Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRECISION: Osimertinib Plus Capivasertib in EGFRm Advanced NSCLC
NCT07486648Phase 2Not yet recruiting
- Sponsor
- Shanxi Cancer Hospital
- Start
- May 2026
- Primary completion
- Oct 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capivasertib in non-small cell lung cancer (NSCLC), sponsored by Shanxi Cancer Hospital. Primary endpoints: Dose-limiting toxicities at 28 days, Adverse events and serious adverse events at 44 months and 2 more. Planned start May 2026; status: not yet recruiting.
02
Drugs
capivasertib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07486648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07486648.